Skin cancers are the most common groups of cancers diagnosed worldwide.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Our lead drug candidate BO-112 is a best-in-class intra-lesional RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
Highlight Therapeutics is revolutionizing dermato-oncology with cutting-edge treatments that target the root causes of skin conditions. Our innovative research and therapies offer new hope for healthier, more resilient skin.
BO-112 monotherapy
A Multicenter, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High-Risk Basal Cell Carcinoma.
Independent
